SCHEMBL2040082

SCHEMBL2040082

COc1cncc(NCc2ccccc2O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.56
HPGD P15428 3/20 0.56
HTT P42858 3/20 0.56
RAB9A P51151 3/20 0.56
LMNA P02545 3/20 0.56
NPC1 O15118 2/20 0.56
ALDH1A1 P00352 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
GFER P55789 1/20 0.56
MAPT P10636 7/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
NOX4 Q9NPH5 2/20 0.50
EGFR P00533 1/20 0.50
TDP1 Q9NUW8 1/20 0.48
GPR55 Q9Y2T6 1/20 0.48
GAA P10253 2/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2044844 0.81 MAPT (0.66) KDM4EHPGDHTTRAB9ALMNA
SCHEMBL27912688 0.81 MAPT (0.66) KDM4EHPGDHTTRAB9ALMNA
SCHEMBL27769271 0.79 MAPT (0.68) HPGDHTTRAB9AALDH1A1MAPT
SCHEMBL2040436 0.78 MAPT (0.58) KDM4EHPGDHTTRAB9ALMNA
SCHEMBL2043293 0.78 HPGD (0.56) KDM4EHPGDHTTRAB9ALMNA
SCHEMBL2036868 0.78 MAPT (0.59) KDM4EHPGDHTTRAB9ALMNA
SCHEMBL2038838 0.77 KDM4E (0.55) KDM4EHPGDHTTRAB9ALMNA
SCHEMBL2038512 0.75 RAB9A (0.52) KDM4EHPGDHTTRAB9ALMNA
SCHEMBL2037443 0.74 MAPT (0.64) KDM4EHPGDHTTRAB9ALMNA
SCHEMBL3254598 0.73 KDM4E (0.59) KDM4EHPGDHTTRAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2516399-B1 PHENOLIC DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RES & DEV (FR) 2018-04-18 EP claimed
US-9120753-B2 Phenol derivatives and pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2015-09-01 US claimed
US-20130172564-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-07-04 US claimed
EP-2516399-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF Galderma Research & Development (FR) 2012-10-31 EP claimed
WO-2011077044-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-06-30 WO claimed
EP-2516399-B1 PHENOLIC DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RES & DEV (FR) 2018-04-18 EP disclosed
US-9120753-B2 Phenol derivatives and pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2015-09-01 US disclosed
US-20130172564-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-07-04 US disclosed
EP-2516399-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF Galderma Research & Development (FR) 2012-10-31 EP disclosed
WO-2011077044-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172564-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF TYR, MITF, CUTA KDM4E 1468/4885HPGD 90/4885HTT 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.